SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
To donate by check, phone, or other method, see our More Ways to Give page.
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
Family hold a rally to call for justice for Fredreca Ford, 29, an inmate at the Franklin County Correction Center on Jackson Pike in Columbus, Ohio, who was found unconscious in her cell on June 26, 2021, and later died that day. It is suspected that Ford overdosed on fentanyl. (Photo: Stephen Zenner/SOPA Images/LightRocket via Getty Images)
A group of civil rights advocates on Thursday urged members of Congress to reject a Biden administration proposal to permanently reclassify fentanyl-related substances as Schedule I drugs, calling the approach toward the synthetic opioids a dangerous continuation of the so-called war on drugs that will do little to quell what is a public health issue.
"If Congress accepts President Biden's misguided recommendations, it will undermine the movement for criminal justice reform."
"Congress must chart a new course to save lives," said Maritza Perez, director of the Office of National Affairs at the Drug Policy Alliance, in a statement noting the record-high number of drug overdose deaths, which have been driven in part by fentanyl.
"The only way forward," she said, "is moving health-centered legislation that can provide lifesaving harm reduction services and evidence-based treatment for people who use drugs. Anything less is not a solution--it's a cop-out for Congress."
The renewed call from Perez and groups including the Leadership Conference on Civil and Human Rights came as the House Energy and Commerce Committee's health panel held a hearing about the proposal the administration rolled out in September.
Under the interagency plan, a Trump-era policy would continue by permanently placing fentanyl-related substances, or fentanyl analogues, into Schedule I--a designation that currently covers substances including ecstasy and heroin, is aimed at drugs with "no currently accepted medical use and a high potential for abuse," and can lead to stiffer penalties.
Drug reform advocates say that approach, in place since 2018, has been an abject failure, worsening racial disparities in the criminal justice system while failing to prevent overdoses or a stem the opioid epidemic.
In a joint statement, the groups noted that at Thursday's House hearing, speakers included representatives from the Office of National Drug Control Policy, Drug Enforcement Administration, Department of Justice, Food and Drug Administration, and National Institutes of Health--but no witness from a drug reform group.
Rather than craft new legislation or pass proposed legislation to enact the administration's plan, the group said that a "compassionate" and "public health-centered approach" must be the way forward.
Related Content
"If Congress accepts President [Joe] Biden's misguided recommendations, it will undermine the movement for criminal justice reform," Aamra Ahmad, senior legislative counsel with the ACLU's National Political Advocacy Department, said in a statement. "Each and every member of Congress has a decision to make: Continue to lock up Black and brown people and hope overdoses magically stop, or give people the resources and support to lead healthy, dignified lives."
Marta Nelson, director of government strategy at the Vera Institute of Justice, concurs.
"The facts don't support the argument that a harsh law enforcement approach, such as permanent classwide scheduling of fentanyl-related substances, will curb drug distribution, sale, and use," said Nelson, noting that "overdose deaths have sadly skyrocketed" since 2018.
"Congress and the administration should instead center an evidence-based public health approach to saving lives now lost to overdose," she said, "and futures lost to long incarcerative sentences dictated by classwide scheduling."
Dear Common Dreams reader, The U.S. is on a fast track to authoritarianism like nothing I've ever seen. Meanwhile, corporate news outlets are utterly capitulating to Trump, twisting their coverage to avoid drawing his ire while lining up to stuff cash in his pockets. That's why I believe that Common Dreams is doing the best and most consequential reporting that we've ever done. Our small but mighty team is a progressive reporting powerhouse, covering the news every day that the corporate media never will. Our mission has always been simple: To inform. To inspire. And to ignite change for the common good. Now here's the key piece that I want all our readers to understand: None of this would be possible without your financial support. That's not just some fundraising cliche. It's the absolute and literal truth. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. Will you donate now to help power the nonprofit, independent reporting of Common Dreams? Thank you for being a vital member of our community. Together, we can keep independent journalism alive when it’s needed most. - Craig Brown, Co-founder |
A group of civil rights advocates on Thursday urged members of Congress to reject a Biden administration proposal to permanently reclassify fentanyl-related substances as Schedule I drugs, calling the approach toward the synthetic opioids a dangerous continuation of the so-called war on drugs that will do little to quell what is a public health issue.
"If Congress accepts President Biden's misguided recommendations, it will undermine the movement for criminal justice reform."
"Congress must chart a new course to save lives," said Maritza Perez, director of the Office of National Affairs at the Drug Policy Alliance, in a statement noting the record-high number of drug overdose deaths, which have been driven in part by fentanyl.
"The only way forward," she said, "is moving health-centered legislation that can provide lifesaving harm reduction services and evidence-based treatment for people who use drugs. Anything less is not a solution--it's a cop-out for Congress."
The renewed call from Perez and groups including the Leadership Conference on Civil and Human Rights came as the House Energy and Commerce Committee's health panel held a hearing about the proposal the administration rolled out in September.
Under the interagency plan, a Trump-era policy would continue by permanently placing fentanyl-related substances, or fentanyl analogues, into Schedule I--a designation that currently covers substances including ecstasy and heroin, is aimed at drugs with "no currently accepted medical use and a high potential for abuse," and can lead to stiffer penalties.
Drug reform advocates say that approach, in place since 2018, has been an abject failure, worsening racial disparities in the criminal justice system while failing to prevent overdoses or a stem the opioid epidemic.
In a joint statement, the groups noted that at Thursday's House hearing, speakers included representatives from the Office of National Drug Control Policy, Drug Enforcement Administration, Department of Justice, Food and Drug Administration, and National Institutes of Health--but no witness from a drug reform group.
Rather than craft new legislation or pass proposed legislation to enact the administration's plan, the group said that a "compassionate" and "public health-centered approach" must be the way forward.
Related Content
"If Congress accepts President [Joe] Biden's misguided recommendations, it will undermine the movement for criminal justice reform," Aamra Ahmad, senior legislative counsel with the ACLU's National Political Advocacy Department, said in a statement. "Each and every member of Congress has a decision to make: Continue to lock up Black and brown people and hope overdoses magically stop, or give people the resources and support to lead healthy, dignified lives."
Marta Nelson, director of government strategy at the Vera Institute of Justice, concurs.
"The facts don't support the argument that a harsh law enforcement approach, such as permanent classwide scheduling of fentanyl-related substances, will curb drug distribution, sale, and use," said Nelson, noting that "overdose deaths have sadly skyrocketed" since 2018.
"Congress and the administration should instead center an evidence-based public health approach to saving lives now lost to overdose," she said, "and futures lost to long incarcerative sentences dictated by classwide scheduling."
A group of civil rights advocates on Thursday urged members of Congress to reject a Biden administration proposal to permanently reclassify fentanyl-related substances as Schedule I drugs, calling the approach toward the synthetic opioids a dangerous continuation of the so-called war on drugs that will do little to quell what is a public health issue.
"If Congress accepts President Biden's misguided recommendations, it will undermine the movement for criminal justice reform."
"Congress must chart a new course to save lives," said Maritza Perez, director of the Office of National Affairs at the Drug Policy Alliance, in a statement noting the record-high number of drug overdose deaths, which have been driven in part by fentanyl.
"The only way forward," she said, "is moving health-centered legislation that can provide lifesaving harm reduction services and evidence-based treatment for people who use drugs. Anything less is not a solution--it's a cop-out for Congress."
The renewed call from Perez and groups including the Leadership Conference on Civil and Human Rights came as the House Energy and Commerce Committee's health panel held a hearing about the proposal the administration rolled out in September.
Under the interagency plan, a Trump-era policy would continue by permanently placing fentanyl-related substances, or fentanyl analogues, into Schedule I--a designation that currently covers substances including ecstasy and heroin, is aimed at drugs with "no currently accepted medical use and a high potential for abuse," and can lead to stiffer penalties.
Drug reform advocates say that approach, in place since 2018, has been an abject failure, worsening racial disparities in the criminal justice system while failing to prevent overdoses or a stem the opioid epidemic.
In a joint statement, the groups noted that at Thursday's House hearing, speakers included representatives from the Office of National Drug Control Policy, Drug Enforcement Administration, Department of Justice, Food and Drug Administration, and National Institutes of Health--but no witness from a drug reform group.
Rather than craft new legislation or pass proposed legislation to enact the administration's plan, the group said that a "compassionate" and "public health-centered approach" must be the way forward.
Related Content
"If Congress accepts President [Joe] Biden's misguided recommendations, it will undermine the movement for criminal justice reform," Aamra Ahmad, senior legislative counsel with the ACLU's National Political Advocacy Department, said in a statement. "Each and every member of Congress has a decision to make: Continue to lock up Black and brown people and hope overdoses magically stop, or give people the resources and support to lead healthy, dignified lives."
Marta Nelson, director of government strategy at the Vera Institute of Justice, concurs.
"The facts don't support the argument that a harsh law enforcement approach, such as permanent classwide scheduling of fentanyl-related substances, will curb drug distribution, sale, and use," said Nelson, noting that "overdose deaths have sadly skyrocketed" since 2018.
"Congress and the administration should instead center an evidence-based public health approach to saving lives now lost to overdose," she said, "and futures lost to long incarcerative sentences dictated by classwide scheduling."